To observe and determine the safety, tolerability, cellular pharmacokinetics and efficacy of TCRx T cells in patients with advanced or recurrent gastric/gastroesophageal junction cancer after failure of first chemotherapy.
Age 18-70 years old;
Histologically confirmed advanced/locally advanced or metastatic gastric cancer at the stomach or gastroesophageal junction, progressed after first-line chemotherapy, or recurrence after gastric/gastroesophageal junction surgery combined with neoadjuvant/adjuvant chemotherapy
Expected survival time ≥ 3 months
Eastern Cooperative Oncology Group (ECOG) score 0-2
Patients with previous non-gastric/gastroesophageal junction malignant tumor
History of severe acute allergy
There is an uncontrolled infection
History or clinical evidence of central nervous system (CNS) metastasis or leptomeningeal carcinomatosis
Single group
Tcrx T cell
Biological/VaccineSequential IV infusion
tumor volume
RECIST 1.1
Overall Survival
The time from randomization to death due to any reason.
AEs
CTCAE5.0
Click on the lead sponsor to view all of their trials.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
TCRx Therapeutics Co.Ltd
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
